Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) EBT Margin (2018 - 2025)

Historic EBT Margin for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to 41.09%.

  • Exagen's EBT Margin fell 8900.0% to 41.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.86%, marking a year-over-year increase of 4500.0%. This contributed to the annual value of 27.14% for FY2024, which is 178700.0% up from last year.
  • Latest data reveals that Exagen reported EBT Margin of 41.09% as of Q3 2025, which was down 8900.0% from 25.59% recorded in Q2 2025.
  • In the past 5 years, Exagen's EBT Margin ranged from a high of 19.69% in Q2 2024 and a low of 192.87% during Q2 2022
  • Over the past 5 years, Exagen's median EBT Margin value was 41.09% (recorded in 2025), while the average stood at 56.55%.
  • As far as peak fluctuations go, Exagen's EBT Margin crashed by -1426900bps in 2022, and later surged by 1574100bps in 2023.
  • Exagen's EBT Margin (Quarter) stood at 54.2% in 2021, then crashed by -117bps to 117.76% in 2022, then skyrocketed by 66bps to 40.25% in 2023, then surged by 32bps to 27.46% in 2024, then plummeted by -50bps to 41.09% in 2025.
  • Its last three reported values are 41.09% in Q3 2025, 25.59% for Q2 2025, and 24.21% during Q1 2025.